blue cross blue shield glp-1 of MA to widely stop covering weight loss drugs IBX members face GLP-1 drug
Description
PYY(336) is currently under investigation for use in the treatment of obesity, and it also suppresses appetite 4,9,13,24 Interestingly, exaggerated secretion of GLP-1 and PYY(336) occurs in some gastric bypass (RYGB) surgery patients, and these alterations correlate with long-term appetite suppression and weight-loss that is associated with such surgery 25
D.et al (2021)
Since that time, 36 more cases have been added to the lawsuit
Why this is so common: Many women with obesity have been told lose weight and you might get pregnant someday, but they dont expect it to happen so quickly
The gastrointestinal adverse event profile of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes [abstract]
